Allogene Therapeutics, Inc.
ALLO Nasdaq
SEC CIK 1737287
Follow Allogene Therapeutics
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$50.4M
−21.7% vs same quarter last year
EPS, diluted
−$0.15
+21.1% vs same quarter last year
Operating cash flow
−$36.1M
−21.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $0 | −$190.9M |
| FY24 | $22K | −$257.6M |
| FY23 | $95K | −$327.3M |
| FY22 | $156K | −$340.4M |
| FY21 | $114.1M | −$182.1M |
| FY20 | $0 | −$316.4M |
| FY19 | $0 | −$184.6M |
| FY18 | - | −$211.5M |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | - | - |
| FY24 | −1241813.6% | −1170863.6% |
| FY23 | −344986.3% | −344489.5% |
| FY22 | −215087.2% | −218214.1% |
| FY21 | −157.9% | −159.6% |
| FY20 | - | - |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$149.6M |
| FY24 | −$201M |
| FY23 | −$239.2M |
| FY22 | −$225.7M |
| FY21 | −$206.3M |
| FY20 | −$181.1M |
| FY19 | −$188.1M |
| FY18 | −$47.9M |
| FY17 | - |
- Allogene Therapeutics
- Healthcare median
Show the numbers
| Year | Allogene Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | −1170863.6% | −47% |
| FY23 | −344489.5% | −58% |
| FY22 | −218214.1% | −80.4% |
| FY21 | −159.6% | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |